Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894498 | PMC |
| http://dx.doi.org/10.1053/j.ajkd.2022.02.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acceptance of COVID-19 vaccine and its related determinants in Nigeria: An online survey.
World J Virol
December 2024
Department of Medical Laboratory Science, School of Public and Allied Health, Babcock University, Ilishan-Remo, OG 121109, Nigeria.
Background: Vaccine hesitancy is a major challenge in the fight against the coronavirus disease 2019 (COVID-19) pandemic. Identifying the sociodemographic factors associated with vaccine acceptance among Nigerians is crucial for improving vaccine uptake.
Aim: To assess the acceptance rate of COVID-19 vaccine and its related determinants among Nigerians.
"They need to speak a language everyone can understand": Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities.
Vaccine
December 2024
Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Accessible vaccine information is one vital component of effective vaccination programs, however, there is limited research that explores how people with disabilities engage with public health messaging. This study aimed to understand how adults with intellectual and developmental disabilities (IDD) and their caregivers navigated Canada's public health communications regarding COVID-19 vaccines. A national survey on the accessibility of vaccine information was conducted in the spring and summer of 2022.
View Article and Find Full Text PDFImmunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Expert Rev Vaccines
December 2024
Guangzhou Patronus Biotech Co, Ltd, Guangzhou, China.
Background: LYB001 is a recombinant protein COVID-19 vaccine displaying a receptor-binding domain (RBD) in a highly immunogenic array on virus-like particles (VLPs). This study assessed the immunogenicity and safety of LYB001 as a booster.
Research Design And Methods: In this randomized, active-controlled, double-blinded, phase 3 trial, participants aged ≥18 years received a booster with LYB001 or ZF2001 (Recombinant COVID-19 Vaccine).
Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents.
EClinicalMedicine
January 2025
Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Background: The impact of pre-infection vaccination on the risk of long COVID remains unclear in the pediatric population. We aim to assess the effectiveness of BNT162b2 on long COVID risks with various strains of the SARS-CoV-2 virus in children and adolescents, using comparative effectiveness methods. We further explore if such pre-infection vaccination can mitigate the risk of long COVID beyond its established protective benefits against SARS-CoV-2 infection using causal mediation analysis.
View Article and Find Full Text PDFSociopolitical antecedents influencing COVID-19 vaccine uptake in Pima County, Arizona.
Vaccine X
January 2025
Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, United States of America.
Introduction: Vaccine hesitancy among marginalized populations particularly in the Hispanic community over the course of the COVID-19 pandemic has presented as a public health issue. This study examined the relationship between political affiliation and vaccination decisions of Hispanic adults in Pima County, Arizona.
Methods: Between January and October 2022, 623 participants completed surveys in English or Spanish after completing informed consent process.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!